Home / Market News / $REGN

$REGN news and market catalysts

The 45 most recent market catalysts affecting $REGN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

45 catalysts 6 high impact 39 bullish 1 bearish Pharmaceuticals
Nov 19, 2026 Corporate Catalyst Bullish Impact 85
FDA Approves Regeneron's Livsayis for Generalized Myasthenia Gravis
Regeneron Pharmaceuticals received FDA approval for Livsayis (cemdisiran) to treat generalized myasthenia gravis (gMG) in adult patients. This is a significant event for Regeneron …
Nov 17, 2026 Corporate Catalyst Bullish Impact 55
Regeneron Receives European Commission Approval for Extended Libtayo Dosing and Faster Infusion Times
Regeneron announced that the European Commission approved an alternative, more flexible dosing schedule and faster infusion times for its cancer drug, Libtayo. This approval allows…
Nov 17, 2026 Corporate Catalyst Bullish Impact 55
Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,075 From $917
Barclays has raised its price target for Regeneron Pharmaceuticals (REGN) from $917 to $1,075. This adjustment reflects Barclays' updated valuation assessment of the biotechnology …
Nov 12, 2026 Corporate Catalyst Neutral Impact 65
Regeneron Announces Results from Phase 2 PINNACLE Trial of Baloncibart in POTS
Regeneron Pharmaceuticals announced the results of its Phase 2 PINNACLE trial for baloncibart, an investigational drug for POTS. This is a significant event for Regeneron as it pro…
Nov 10, 2026 Corporate Catalyst Bullish Impact 55
Soleo Health Named Specialty Pharmacy Partner for Regeneron's Pasatru™
Regeneron Pharmaceuticals has chosen Soleo Health as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), an FDA-approved treatment for fibrodysplasia ossificans progressiv…
Nov 9, 2026 Corporate Catalyst Bullish Impact 75
Regeneron Announces Positive First-in-Human Trial Results for CIDEBsiRNA in MASLD Patients
Regeneron announced promising initial results from a first-in-human clinical trial for CIDEBsiRNA, an investigational treatment for MASLD. The therapy showed rapid normalization of…
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
DZ Bank Adjusts Price Target on Regeneron Pharmaceuticals
DZ Bank has revised its price target for Regeneron Pharmaceuticals (REGN) upwards from $900 to $1,067. This change signifies a more favorable valuation perspective from the analyst…
Nov 4, 2026 Corporate Catalyst Neutral Impact 55
Bank of America Adds Regeneron to 'Value 10' Portfolio
Bank of America Securities has included Regeneron Pharmaceuticals in its 'Value 10' portfolio for November 2026. This is significant for Regeneron as it signals a quantitative endo…
Nov 3, 2026 Corporate Catalyst Neutral Impact 55
Wall Street Analysts Update Ratings and Price Targets for Regeneron Pharmaceuticals
On November 3, 2026, multiple Wall Street analysts updated their research on Regeneron Pharmaceuticals. Notably, UBS and Guggenheim both maintained 'Buy' ratings and raised their p…
Nov 2, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Markets Adjusts Regeneron Pharmaceuticals Price Target to $913
RBC Capital Markets has adjusted its price target for Regeneron Pharmaceuticals (REGN) upwards to $913 from $810. This change indicates a more optimistic valuation by RBC analysts …
Nov 2, 2026 Corporate Catalyst Neutral Impact 65
Analysts Adjust Price Targets for Regeneron Pharmaceuticals
On November 2, 2026, multiple financial institutions, including Cantor Fitzgerald, Bernstein, Leerink Partners, and Canaccord Genuity, significantly raised their price targets for …
Nov 2, 2026 Corporate Catalyst Bullish Impact 85
Cemdisiran Phase 3 Trial Results and FDA Status Update
Regeneron and Alnylam announced positive Phase 3 trial results for their drug Cemdisiran, which demonstrated significant improvements in patients with generalized myasthenia gravis…
Nov 2, 2026 Corporate Catalyst Bullish Impact 55
Leerink Partners Adjusts Price Target on Regeneron Pharmaceuticals to $997 From $835
Leerink Partners has raised its price target for Regeneron Pharmaceuticals (REGN) by a significant margin, from $835 to $997. This upward revision suggests that Leerink sees greate…
Oct 30, 2026 Corporate Catalyst Bullish Impact 95
Regeneron Reports Q3 2026 Financial Results, Expanded Sanofi Collaboration, and FDA Approval of Pasatru
Regeneron's Q3 2026 results significantly beat expectations, driven by strong sales of key drugs. This financial performance, combined with the expanded strategic alliance with San…
Oct 28, 2026 Corporate Catalyst Bullish Impact 55
Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $850 From $900
Evercore ISI, a prominent investment bank, has reduced its price target for Regeneron Pharmaceuticals (REGN) from $900 to $850. This downward revision suggests that the analyst fir…
Oct 28, 2026 Corporate Catalyst Bullish Impact 65
Canaccord Genuity Adjusts Price Target on Regeneron Pharmaceuticals
Canaccord Genuity's decision to raise Regeneron Pharmaceuticals' price target from $875 to $922 is a direct consequence of the company securing an extended contract with the U.S. g…
Oct 28, 2026 Corporate Catalyst Bullish Impact 55
Regeneron and Amgen Narrow Scope of Eylea Biosimilar Lawsuit
Regeneron and Amgen have announced a procedural update in their legal dispute over biosimilar versions of Eylea, indicating they have narrowed the scope of the lawsuit. This develo…
Oct 26, 2026 Corporate Catalyst Bullish Impact 55
Regeneron Secures $270 Million U.S. Contract Extension for Ebola Treatment Inmazeb
Regeneron Pharmaceuticals announced an extension of its supply agreement with BARDA for its Ebola treatment, Inmazeb, valued at approximately $270 million through 2031. This is a p…
Oct 25, 2026 Corporate Catalyst Bullish Impact 75
Regeneron Announces Long-Term Phase 3 C-POST Trial Data for Libtayo in High-Risk CSCC
Regeneron announced updated long-term results from its Phase 3 C-POST trial for Libtayo in high-risk CSCC, demonstrating a further reduction in the risk of death over nearly four y…
Oct 22, 2026 Corporate Catalyst Bullish Impact 55
Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850
Evercore ISI, a prominent investment bank, has raised its price target for Regeneron Pharmaceuticals (REGN) from $850 to $900. This adjustment indicates that the analyst firm has u…
Oct 19, 2026 Corporate Catalyst Bullish Impact 55
Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865
Piper Sandler's analyst Biren Amin reiterated an 'Overweight' rating on Regeneron Pharmaceuticals (REGN) and slightly raised the price target from $854 to $865. This action signals…
Oct 16, 2026 Corporate Catalyst Bullish Impact 65
Regeneron Pharma Says EMA’s CHMP Adopts Positive Opinion Recommending Approval Of Alternative Dosing Schedule For Libtayo Across All Approved Indications
The European Medicines Agency's CHMP has adopted a positive opinion recommending an alternative, less frequent dosing schedule for Regeneron's cancer drug, Libtayo, across all appr…
Oct 15, 2026 Corporate Catalyst Bullish Impact 75
UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978
UBS analyst Trung Huynh upgraded Regeneron Pharmaceuticals from a 'Neutral' to a 'Buy' rating, simultaneously raising the price target from $660 to $978. This substantial increase …
Oct 12, 2026 Corporate Catalyst Bullish Impact 75
Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth
Regeneron Pharmaceuticals (REGN) released encouraging 84-week findings from its Phase 3 OPTIMA trial for Pasatru, a drug for the ultra-rare FOP condition. The data showed sustained…
Oct 12, 2026 Corporate Catalyst Bullish Impact 75
Regeneron Pharmaceuticals Announces Data From Its Phase 3 OPTIMA Study Of Pasatru To Treat Fibrodysplasia Ossificans Progressiva Shows Efficacy In Stopping New Bone Growth; Trial Meets Primary Endpoint By Reducing 90% New Heterotopic Ossification Lesions
Regeneron announced positive 84-week data from its Phase 3 OPTIMA trial for Pasatru, a drug for Fibrodysplasia Ossificans Progressiva (FOP). The data showed sustained efficacy in h…
Oct 8, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810
RBC Capital's analyst Brian Abrahams maintained a 'Sector Perform' rating on Regeneron Pharmaceuticals while raising the price target from $737 to $810. This action signals a conti…
Oct 7, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780
Truist Securities analyst Gregory Renza has maintained a 'Buy' rating on Regeneron Pharmaceuticals (REGN) and raised the price target from $772 to $780. This action signals continu…
Oct 6, 2026 Corporate Catalyst Bullish Impact 65
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950
JP Morgan analyst Chris Schott has reaffirmed a positive stance on Regeneron Pharmaceuticals (REGN) by maintaining an 'Overweight' rating and raising the price target from $900 to …
Oct 2, 2026 Corporate Catalyst Bullish Impact 75
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data
Regeneron's announcement of promising Phase 1/2 data for ubamatamab in ovarian cancer and Phase 2 data for trevogrumab in muscle preservation is a significant corporate catalyst. T…
Oct 1, 2026 Corporate Catalyst Bullish Impact 75
Regeneron Pharmaceuticals Announces Its Results From Phase 2 COURAGE Study Of Trevogrumab Shows 70% Prevention Of Muscle Loss Associated With Semaglutide Treatment; Lower Dose Of Trevogrumab Did Not Enhance Weight Loss Achieved With Semaglutide Alone
Regeneron announced positive Phase 2 results for trevogrumab, demonstrating a 70% prevention of muscle loss when combined with semaglutide. This is significant because muscle loss …
Oct 1, 2026 Corporate Catalyst Bullish Impact 85
Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion
Sanofi and Regeneron are extending their highly successful 20-year antibody partnership, which has already yielded the blockbuster drug Dupixent. This expansion involves Sanofi mak…
Oct 1, 2026 Corporate Catalyst Bullish Impact 75
Regeneron Exec Says Co. Eligible To Receive $1B In Potential Milestone Payment With Start Of First Late-Stage Trial As Part Of Deal
Regeneron Pharmaceuticals has disclosed that it is eligible to receive a $1 billion milestone payment. This payment is contingent upon the initiation of the first late-stage clinic…
Sep 28, 2026 Corporate Catalyst Bearish Impact 75
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
Kodiak Sciences announced positive Phase 3 data for its wAMD drug, Zenkuda, showing non-inferiority to Regeneron's Eylea, a major revenue driver for REGN. This is significant becau…
Sep 10, 2026 Corporate Catalyst Bullish Impact 55
HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920
HSBC analyst Rajesh Kumar has maintained a 'Buy' rating on Regeneron Pharmaceuticals (REGN) and significantly raised its price target from $800 to $920. This analyst action signals…
Aug 20, 2026 Corporate Catalyst Bullish Impact 75
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug
Regeneron Pharmaceuticals (REGN) has secured FDA approval for Pasatru (garetosmab-grts), a drug targeting fibrodysplasia ossificans progressiva (FOP), an ultra-rare bone disorder. …
Aug 19, 2026 Corporate Catalyst Bullish Impact 85
Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans Progressiva
Regeneron Pharmaceuticals received FDA approval for Pasatru, a drug designed to treat fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. This approval is a signi…
Aug 6, 2026 Corporate Catalyst Neutral Impact 65
LibtayoReceives Health Canada Approval for Adjuvant Treatment Of High-Risk Cutaneous Squamous Cell Carcinoma
The filing discloses that Libtayo (cemiplimab), a drug developed by Regeneron and Sanofi, has received Health Canada approval for the adjuvant treatment of high-risk cutaneous squa…
Aug 3, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030
Guggenheim analyst Brad Canino maintained a 'Buy' rating on Regeneron Pharmaceuticals (REGN) and raised the price target from $1000 to $1030. This action signals continued bullish …
Jul 31, 2026 Corporate Catalyst Bullish Impact 75
Regeneron Pharmaceuticals shares are trading higher after multiple analysts raised their respective price targets on the stock.
This headline signals a strong positive sentiment for Regeneron Pharmaceuticals, driven by professional analysts. Increased price targets often lead to increased investor confidenc…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $737
RBC Capital analyst Brian Abrahams reiterated a 'Sector Perform' rating on Regeneron Pharmaceuticals (REGN) but raised the price target from $696 to $737. This action suggests that…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $795
Cantor Fitzgerald analyst Carter Gould maintained an 'Overweight' rating on Regeneron Pharmaceuticals and raised the price target from $750 to $795. This action signals continued c…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $772
Truist Securities analyst Gregory Renza maintained a 'Buy' rating on Regeneron Pharmaceuticals and raised the price target from $769 to $772. This action signals continued confiden…
Jul 30, 2026 Corporate Catalyst Bullish Impact 75
Regeneron Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
Regeneron's strong Q2 earnings are a direct corporate catalyst, indicating robust company-specific performance. This positive news primarily impacts REGN shares, driving them highe…
Jul 30, 2026 Corporate Catalyst Bullish Impact 92
Regeneron Pharmaceuticals Q2 Adj. EPS $14.29 Beats $10.26 Estimate, Sales $4.291B Beat $3.816B Estimate
Regeneron Pharmaceuticals (REGN) announced Q2 adjusted EPS of $14.29, significantly exceeding the analyst consensus of $10.26, and sales of $4.291 billion, beating the $3.816 billi…
Jul 21, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1000
Guggenheim analyst Brad Canino maintained a 'Buy' rating on Regeneron Pharmaceuticals (REGN) and raised the price target from $995 to $1000. This action signals continued analyst c…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.